In vivo studies show superior antitumor activity of ADCT-402 against CD19-positive lymphoma than maytansinoid or auristatin based therapy.121 A phase 1 trial of ADCT-402 for relapsed/refractory ALL is underway (NCT02669264). This evidence concerns the gene CD19 and lymphoma.